3.64 USD
▲-0.12+0.28%
盘后 3.65 +0.55%
2026-08-03
市值
$240.50M
市盈率
—
EPS
-0.38
股息率
—
52 周区间
1.30 – 4.85
成交量
113.18K
Beta
0.58
目标价
10.74
52W 低 1.3052W 高 4.85
价格走势
公司简介
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ...